Investor Presentation

Ref: Akums/Exchange/2026-27/39 August 08, 2026 To, To, The Listing Department The Listing Department National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, C-1, Block G, 25th Floor, New Trading Ring, Bandra Kurla Complex, Rotunda Building, Phiroze Jeejeebhoy Bandra (E), Mumbai – 400 051 Towers, Dalal Street, Mumbai – 400 001 Symbol: AKUMS Scrip Code: 544222 Sub Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation Pursuant to Regulation 30 read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of investor presentation is enclosed herewith for the Earning/Quarterly conference call (group meet) going to be held on August 10, 2026, virtually. A copy of this disclosure is being updated on the website of Akums Drugs and Pharmaceuticals Limited at www.akums.in This is for your information and records Thanking You For Akums Drugs and Pharmaceuticals Limited Dharamvir Malik Company Secretary & Compliance Officer Encl: As above Q1 FY 26-27 Investor Presentation August 2026 Disclaimer Akums Drugs and Pharmaceuticals Limited may, from time to time, make written and oral forward-looking statements, in addition to statements contained in the company's filings with BSE Limited (BSE) and National Stock Exchange of India Limited (NSE), and its reports to shareholders. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Akums Drugs and Pharmaceuticals Limited. All information contained in this presentation has been prepared solely by Akums Drugs and Pharmaceuticals Limited. Akums Drugs and Pharmaceuticals Limited does not accept any liability whatsoever for any loss, howsoever, arising from any use or reliance on this presentation or its contents or otherwise arising in connection therewith. Managing Directors’ Message Dear Investors We are pleased to announce the results for Q1 FY27. We have begun FY27 on a strong and encouraging note. We registered a healthy revenue growth of over 13% with EBIDTA increasing by more than 30%. The growth was primarily led by CDMO segment characterized by double- digit volume growth along with improvement in API prices. The consistent performance of CDMO showcases healthy demand environment as well as our clients’ trust in Akums as the preferred manufacturing partner. API segment continued on its journey towards becoming EBIDTA positive as higher share of non-cepha products led to better gross margins. The trade generic segment remained EBIDTA positive during the quarter. Our domestic branded formulations segment, restarted its growth journey with a healthy 7% revenue growth during the quarter, margins were impacted due to increase in field force strength for additional territories. We expect improved performance from this segment going forward. Our international branded formulations business had a muted quarter but is expected to return to growth as we remain confident of the structural attractiveness of our chosen geographies. On 23rd July, we announced the acquisition of Oriflame India’s Manufacturing business. The transaction covers two manufacturing facilities along with a leased warehouse for a total consideration of Rs 56 Crore. With this acquisition, we expand our manufacturing footprint in skincare cosmetics and wellness products. This is in-line with our strategy of tapping into niche formulations to improve our positioning among existing as well as prospective clients and augment our margins. We extend our sincere gratitude to all stakeholders and remain committed to creating long term shareholder value and look forward to the year ahead with positivity and confidence. -Sanjeev Jain & Sandeep Jain More than Two Decades’ Legacy of Expertise, Experience & Trust Dedicated facilities for Expanded into Asian markets. Hormones, Cosmetics Established dedicated and Dermatology. Acquired Established R&D lab in Mumbai to manufacturingsite for Parabolic Drugs to Launched Akumentisto venture into regulated market. OralLiquid Dosage venture intoAPI venture into branded Plant 1 ,2 & 3 received EU- & Sterileproducts. formulations. Received US-NSF Certification GMP accreditation Incorporated for MaxcureNutravedicsfacility Set up dedicated in April 2004 Established a Started dedicated plant facility for Penemsat nutraceutical for β-lactam anti- Kotdwar Listed on NSE and BSE Set up of first facility infectives and steroids plant for oral Started new injectable soliddosage facility form in Haridwar. ANVISAcertified for Plant 3 2004 Build 2010 Strengthen 2021 Accelerate 2026 Technologically Advanced Manufacturing Capabilities Location Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Haridwar Kotdwar Baddi Haridwar Year 2004 2007 2007 2010 2010 2010 2014 2014 2021 2023 2024 Annual Capacity 649 15 39 264 6 269 2.635 732 17 392 41 (Cr units) Ayurvedic / β-lactams Penem Capability General General General Hormonal Cosmetics Nutraceuticals General and steroids anti-infective General General 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 Dosage Forms 1 Oral Solid 2 Oral Liquid 3 Injectable / Sterile 4 External / Topical Key Accreditations* *Received by some or all facilities; R&D Focus Illustrative Tablet Bi-layered, Inlay Multiple Tablets Pre-filled In Tablet Sustained Release Tablet in Capsule syringes Tablet in Tablet Lyophilized Smart Gummies Mouth Melting Tri Layered Vials Tablets Powders in Sachet Tablet Innovative In-house Technologies (1) As of 31st March 2025 6 Oriflame – Manufacturing business Acquisition Rationale for Acquisition Transaction Overview Favorable Market Dynamics: • Acquisition of Manufacturing business of • Indian cosmetics market is fast growing Oriflame India for Rs 56 Cr • Multiple growth drivers including rise in • Transaction includes two manufacturing disposable incomes, urbanization, demand for facilities in Noida and Roorkee sustainable products, easy accessibility and rise • Manufacturing of Oriflame products to continue of influencer marketing are some of the key in the facility, plus addition of other CDMO drivers promoting growth in this segment customers to boost revenue from these units Synergies with Akums Capabilities: Unit 1 : Noida Plant • Akums has over a decade of experience in cosmetic manufacturing, through a dedicated Skincare, Personal & hair Care: Creams, Lotions, cosmetic plant (Plant 5) Scrubs, Face wash, Shampoos, Hot fill, Masks, Conditioners, Toners and Serums • Strong interest in recent years, leading to high capacity utilization of Plant 5 Colour Cosmetics: Foundations, Primers, CC & BB • Transaction also marks our foray into the fast- Creams growing color cosmetics segment, while expanding our capacity and capability in Unit 2 : Roorkee Plant skincare and wellness products as well • The facilities are HALAL certified opening the Wellness: Protein Powders, Soft gel capsules, possibilities for exports Tablets and OSD packs Cosmetics: Lipsticks & Slim sticks, Liquid Lipsticks, Mascara & Eye Liners Key drivers as well as their trends during Q1 FY27 Key drivers and their impact on Akums’ performance Strong CDMO Losses in Trade Muted API prices saw volume growth generics and performance in an increase in momentum API business Marketing continues curtailed segments Akums continued to witness API prices saw an increase in Q1 International and domestic Trade generics continues to break double digit volume growth after constant decline in the last 3 branded segments muted for this even; API losses curtailed leading to capacity utilization quarters. Although volatility quarter. Expected to improve significantly. improving to 50%. remains high in Q2. going forward Q1 FY 27 Financial Performance Highlights Q1 FY27 Performance Highlights Consolidated Performance Segment Break-up Business Vertical Share in revenue 205 [Showing first 8,000 characters — download PDF for full document]